title: [MicroRNA expression pattern in intraductal papillary mucinous neoplasm].
abstract: OBJECTIVE
  Intraductal papillary mucinous neoplasms (IPMN) are precursor lesions of fatal pancreatic cancer. Physiological function of microRNA is to regulate the stability and translation of mRNA. The aberrant microRNA expression is commonly observed in many cancers. The aim of this study was to analyze the expression pattern of microRNA in IPMN and evaluate the role of the microRNA.
  
  
  METHODS
  Using two paraffin-embedded IPMN tissues, microRNA expression of normal tissue, IPMN adenoma and carcinoma were compared by cDNA-mediated annealing, selection, extension and ligation microarray assay. Using real time PCR, expression levels of aberrantly up-regulated microRNAs were assessed in another 20 IPMNs, four pancreatic cancer cell lines (Panc1, MiaPaCa-2, XPA-3, BxPC-3) and immortalized pancreatic ductal cell line (HPNE). Effect of suppressing highly over-expressed two microRNAs in pancreatic cancer cell lines with anti-microRNA inhibitors were evaluated using CCK-8 assay.
  
  
  RESULTS
  Among aberrantly expressed 122 microRNAs in IPMN, miR-552, miR-25*, miR-183, miR-1300, miR-196a, miR-182*, and miR-30c-1* were consistently increased more than 3-fold. On average, miR-196a and miR-183 increased 10,824 folds and 26,519 folds in four pancreatic cancer cell lines compared with HPNE. These two microRNAs were also over-expressed in 20 IPMNs compared with HPNE. After applying anti-miRNA inhibitors, cell survival of four pancreatic cancer cell lines decreased by 24.5% with anti-miR-196a and by 14.2% with anti-miR-183 on average.
  
  
  CONCLUSIONS
  Aberrant expression of 122 microRNAs was observed in IPMN. Two microRNAs, miR-196a and miR-183-increased in IPMN and pancreatic cancer cell lines compared with immortalized dancreatic ductal cell line. The inhibitions of these microRNAs repressed cell proliferation of pancreatic cancer cell lines. (Korean J Gastroenterol 2011;58:190-200).
authors: Department of Internal Medicine, Division of Gastroenterology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors: Yun Gyoung
authors: YG
authors: Park
authors: Kwang Hyuck
authors: KH
authors: Lee
authors: Jong Kyun
authors: JK
authors: Lee
authors: Kyu Taek
authors: KT
authors: Lee
authors: Dong Wook
authors: DW
authors: Choi
authors: Seong Ho
authors: SH
authors: Choi
authors: Jin Seok
authors: JS
authors: Heo
authors: Kee Taek
authors: KT
authors: Jang
authors: Eun Mi
authors: EM
authors: Lee
authors: Jung Ok
authors: JO
authors: Kim
authors: Shin Young
authors: SY
authors: Min
authors: Eun Jung
authors: EJ
authors: Kim
mesh_terms: D002288:Adenocarcinoma, Mucinous / Q000175:diagnosis / Q000378:metabolism*; D000236:Adenoma / Q000175:diagnosis / Q000378:metabolism*; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects; D002291:Carcinoma, Papillary / Q000175:diagnosis / Q000378:metabolism*; D002460:Cell Line; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000494:pharmacology; D005260:Female; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000037:antagonists & inhibitors / Q000378:metabolism*; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000378:metabolism*; D060888:Real-Time Polymerase Chain Reaction; D015854:Up-Regulation; D000093542:Gemcitabine
chemical_list: D000964:Antimetabolites, Antineoplastic; C533449:MIRN183 microRNA, human; C542543:MIRN196 microRNA, human; D035683:MicroRNAs; D003841:Deoxycytidine; D000093542:Gemcitabine